ITP
SNDX icon

Iron Triangle Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Iron Triangle Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-973,057
Closed -$23.2M – 37
2024
Q1 		$23.2M Buy
+973,057
New +$21.7M 2.37% 20
2023
Q1 		– Sell
-370,294
Closed -$9.42M – 34
2022
Q4 		$9.42M Buy
+370,294
New +$8.64M 1.69% 21

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Iron Triangle Partners's SNDX Position: Q2 2024 in Review

Iron Triangle Partners sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 973,057 shares — an estimated $23.2M sold.

Iron Triangle Partners first reported a position in SNDX in Q4 2022 and held it in 2 quarters. The position peaked at $23.2M in Q1 2024. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

  • Iron Triangle Partners reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Iron Triangle Partners sold 973,057 Syndax Pharmaceuticals shares in Q2 2024, an estimated $23.2M.
  • Iron Triangle Partners first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Iron Triangle Partners's Syndax Pharmaceuticals position peaked at $23.2M in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on Iron Triangle Partners's 13F filing for Q2 2024, filed 14 Aug 2024.